OncoMatch/Clinical Trials/NCT04787042
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Is NCT04787042 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including ST-067 and Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA] for cancer.
Treatment: ST-067 · Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA] · pembrolizumab — This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab \[Gazyva®\] pre-treatment, by IV infusion, and in combination with pembrolizumab. A Phase 2 monotherapy arm is also planned; the exact design of the Phase 2 study elements with respect to formulation and pre-treatment will be determined after completion of the Phase 1 study portion of the trial.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Melanoma
Renal Cell Carcinoma
Triple-Negative Breast Cancer
Breast Carcinoma
Small Cell Lung Cancer
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: ESR1 wild-type
TNBC is diagnosed in a tumor which does not express estrogen receptor
Required: PR (PGR) wild-type
TNBC is diagnosed in a tumor which does not express ... progesterone receptor
Required: HER2 (ERBB2) wild-type
TNBC is diagnosed in a tumor which ... is not human epidermal growth factor receptor 2 (HER2) 3+ on IHC or is negative by fluorescence in situ hybridization (FISH)
Required: MSH2 wild-type
MSI high tumor should ... be negative for MSH1/2/6 or PMS-2 by IHC
Required: MSH6 wild-type
MSI high tumor should ... be negative for MSH1/2/6 or PMS-2 by IHC
Required: PMS2 wild-type
MSI high tumor should ... be negative for MSH1/2/6 or PMS-2 by IHC
Required: MSH1 wild-type
MSI high tumor should ... be negative for MSH1/2/6 or PMS-2 by IHC
Required: EGFR wild-type
NSCLC (with no EGFR, TRK receptor, or ALK positive mutations/fusions)
Required: NTRK1 wild-type
NSCLC (with no EGFR, TRK receptor, or ALK positive mutations/fusions)
Required: NTRK2 wild-type
NSCLC (with no EGFR, TRK receptor, or ALK positive mutations/fusions)
Required: NTRK3 wild-type
NSCLC (with no EGFR, TRK receptor, or ALK positive mutations/fusions)
Required: ALK wild-type
NSCLC (with no EGFR, TRK receptor, or ALK positive mutations/fusions)
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: high dose chemotherapy requiring stem cell rescue
Prior high dose chemotherapy requiring stem cell rescue
Cannot have received: anti-PD-1/PD-L1/PD-L2 or co-inhibitory T-cell receptor therapy (pembrolizumab)
Exception: only if discontinued due to Grade 3 or higher irAE
Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX40, CD137), and was discontinued from that treatment due to a Grade 3 or higher irAE
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- HonorHealth Research Institute · Scottsdale, Arizona
- Sarah Cannon Research Institute at HealthONE · Denver, Colorado
- Yale Cancer Center · New Haven, Connecticut
- Moffitt Cancer Center · Tampa, Florida
- Massachusetts General Hospital · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify